Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Unicycive Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- 0 vs. Q4 2021
- Shares held
- 1.15M
- +35.2K (+3.2%) vs. Q4 2021
- Total value
- $1.48M
- −$823.0K (−35.8%) vs. Q4 2021
- New holders
- 3
- 2 more added
- Sold out
- 3
- 1 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting UNCY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 79 | $54.6M |
| Q1 2026 | 51 | $65.2M |
| Q4 2025 | 35 | $47.5M |
| Q3 2025 | 30 | $27.4M |
| Q2 2025 | 20 | $24.6M |
| Q1 2025 | 29 | $34.5M |
| Q4 2024 | 31 | $49.0M |
| Q3 2024 | 29 | $19.1M |
| Q2 2024 | 24 | $9.52M |
| Q1 2024 | 23 | $31.6M |
| Q4 2023 | 16 | $11.3M |
| Q3 2023 | 16 | $12.2M |
| Q2 2023 | 15 | $1.38M |
| Q1 2023 | 13 | $3.54M |
| Q4 2022 | 9 | $428.3K |
| Q3 2022 | 12 | $571.0K |
| Q2 2022 | 15 | $992.0K |
| Q1 2022 | 12 | $1.48M |
| Q4 2021 | 12 | $2.30M |
| Q3 2021 | 10 | $3.02M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Unicycive Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 640,633 | $826.0K | 0.06% | −46,123−6.7% | Reduced |
| Board of Trustees of The Leland Stanford Junior University | 247,583 | $319.0K | 0.02% | 00.0% | Unchanged |
| Ayrton Capital LLC | 76,645 | $99.0K | 0.13% | 00.0% | Unchanged |
| Truist Financial Corp | 37,462 | $48.0K | 0.00% | +37,462 | New |
| Citadel Advisors LLC | 37,196 | $48.0K | 0.00% | +37,196 | New |
| Geode Capital Management, LLC | 26,109 | $33.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 24,166 | $31.0K | 0.00% | +8,121+50.6% | Added |
| Vanguard Group Inc | 22,695 | $29.0K | 0.00% | 00.0% | Unchanged |
| Frontier Wealth Management LLC | 18,800 | $20.0K | 0.00% | 00.0% | Unchanged |
| Tandem Capital Management Corp | 15,500 | $17.0K | 0.01% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,841 | $5.00K | 0.00% | +3,841 | New |
| Wells Fargo & Company | 33 | $0 | 0.00% | +1+3.1% | Added |
| UBS Group AG | 0 | $0 | 0.00% | −5,273−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −2−100.0% | Sold out |